TSX Venture: QPT
EDMONTON, Nov. 6, 2017 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products to improve the quality of life, today announced the results of its November 2, 2017 annual general meeting of shareholders.
The Company is pleased to announce the following 5 directors have been elected to the Company's Board of Directors:
Lorne Meikle, BA
J. Mark Lievonen, C.M., FCPA, FCA, LLD
W. John Meekison, CPA, CMA, P.Log, CIM
Shawn Lu, CIM, MFin
Madi R. Madiyalakan, Ph.D.
Mr. Meikle, Mr. Lievonen and Mr. Meekison are all independent directors. Mr. Meikle is the Chairman of the Board. Mr. Meekison is Chair of the Audit Committee. Mr. Lievonen is Chair of the Governance Committee and Mr. Lu is Chair of the Compensation Committee.
"We are pleased with the AGM results and wish to thank our shareholders for their continuing support," said Dr. Madi R. Madiyalakan, Chief Executive Officer for Quest. "I would also like to welcome our 2 newly elected Board members, Mr. Lievonen and Mr. Meekison, who bring a wealth of pharmaceutical and corporate finance experience to the Board. Mr. Lievonen has over 30 years' experience in the biopharmaceutical industry. From 1999 to 2016, Mr. Lievonen was the President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi, a global pharmaceutical company. He was appointed to the Order of Canada in 2015, named a Chevalier de l'Ordre National de Mérite by the government of France in 2007, and was inducted into the Canadian Healthcare Marketing Hall of Fame in 2013. Mr. Meekison is the Chief Financial Officer of Segra International Corp., a private technology company servicing the cannabis sector. From 2005 to 2016, Mr. Meekison was the Chief Financial Officer and co-founder of iCo Therapeutics Inc., a pharmaceutical development company. He is a former investment banker with extensive experience in the areas of corporate finance, capital markets and investment financing. With the strength and experience of our re-elected Board members, Mr. Meikle, Mr. Lu and myself, I am confident that Quest's Board of Directors will be able to help the Company execute its business strategy to add value to our shareholders."
Approximately 73,600,000 shares were voted for the Company's shareholder meeting representing 44% of the Company's shares eligible to vote. Shareholder's voted 99% in favor of all meeting resolutions.
About Quest PharmaTech Inc.
Quest PharmaTech is a publicly traded; Canadian based pharmaceutical company developing products to improve the quality of life. The Company through its subsidiary, OncoQuest and its Chinese joint venture, OncoVent, is developing antibody based immunotherapeutic products for cancer. In addition, the Company owns the Photodynamic Therapy technology for oncology and dermatology applications, licensed to BioCeltran Co., Ltd., a Korea based company (Bioceltran). Quest has an ownership interest in Bioceltran, which is focused on SP Technology™ for transdermal delivery of drugs and photosensitizers for pharmaceutical and cosmetic purposes. Quest through another subsidiary, Madenco Biosciences, also markets consumer health products worldwide, including Bellus Skin™ serum, a premium anti-wrinkle skin care product licensed from Korea. Quest is also developing an antibody licensed from University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.
For further information: Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: email@example.com
Quest is a publicly traded, Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds; and monoclonal antibodies which target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining...
Also from this source: